NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…
Providing the Best Care: Rheumatologists & Professionals Adapt to COVID-19
The new landscape for rheumatologists includes telemedicine, kids out of school and infection-prevention protocols. During the current pandemic, the practice of medicine, research and daily lives are changing to keep providers and patients safe…
Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment
(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…
Activating Yourself in the Time of Coronavirus
A timely and personal appeal to all those who can to become or remain civically active in this critical time.
Inflammation & Psych Issues: A Look at Potential Co-Morbidity
Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…
Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study
No data exist for prescribing hydroxychloroquine for post-exposure prophylaxis, and we should not prescribe it for this indication.
Hundreds of Providers Use RISE for 2019 QPP Reporting
Hundreds of rheumatology providers are using RISE registry data collected from their EHRs over the past year for required 2019 federal reporting.
Commercial Insurers Extend Coverage for Telehealth Services
The ACR has created a chart of temporary changes to commercial payers’ telehealth policies that make it easier for physicians and patients to connect without the need for an office visit.
Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
After a study investigated if hydroxycholoroquine (HCQ) benefits COVID-19 patients, the drug—used to treat SLE and RA patients—began running out in pharmacies around the U.S. ACR leaders have asked the FDA to increase monitoring of the HCQ supply…
COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials
(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus. Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in…
- « Previous Page
- 1
- …
- 219
- 220
- 221
- 222
- 223
- …
- 824
- Next Page »